Press Room MediaRoom Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis - Late-breaking oral abstract presented at the World Congress of Gastroenterology - Mon, 16 Oct 2017 08:07:00 -0400 Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis - Understand AD: A Day in the Life, Raises Awareness of Atopic Dermatitis by Sharing Real Stories from the AD Community, Driving Empathy and Understanding of this Unrelenting, Chronic Disease - Wed, 11 Oct 2017 08:00:00 -0400 Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab) - Praluent continues to be available to patients in the U.S. - Thu, 05 Oct 2017 12:30:00 -0400 Sanofi and Regeneron Announce Approval of Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union - First targeted biologic in the European Union to receive marketing authorization for use in atopic dermatitis - Thu, 28 Sep 2017 07:22:00 -0400 Sanofi and NIH researchers develop "three-in-one" antibodies as a potential breakthrough intervention for HIV/AIDS - In preclinical studies, trispecific antibodies show exceptional potency against diverse HIV viruses - Wed, 20 Sep 2017 14:01:00 -0400